concentrations (MTX) were collected. Delayed plasma excretion was defined as (MTX) ≥1 μM at 42 hours (h). Leucovorin was administered at 42 h and then every 6 h until (MTX) <0.1 μM. Population and individual MTX pharmacokinetic parameters were estimated by nonlinear mixed-effects modeling. Results Fifty-eight patients had intracranial fluid collections present. Population average (inter-individual variation) MTX clearance was 96.0 ml/min/m 2 (41.1 CV %) and increased with age. Of the patients with intracranial fluid collections, 24 had delayed excretion; only 2 of the 17 without fluid collections (P < 0.04) had delayed excretion. Eleven patients had grade 3 or 4 toxicities attributed to HD-MTX. No significant difference was observed in intracranial fluid collection, total leucovorin dosing, or hydration fluids between those with and without toxicity. Conclusions Although an intracranial fluid collection is associated with delayed MTX excretion, HD-MTX can be safely administered with monitoring of infants and young children with intracranial fluid collections. Infants younger than 1 year may need additional monitoring to avoid toxicity.
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Young children with medulloblastoma treated on MTXbased regimens have shown improvement in progressionfree and overall survival [6, 7, 9] . Methotrexate disposition in infants and very young children with brain tumors, however, is unknown despite similar studies in children with acute leukemia [10] [11] [12] [13] [14] [15] [16] . Pharmacokinetic evaluation of MTX in infants with acute lymphoblastic leukemia (ALL) enrolled on Pediatric Oncology Group 9407 study showed that older infants (e.g., 7-12 months) had a 25 % higher average methotrexate clearance than younger infants (e.g., 0-6 months); younger infants, correspondingly, had a higher incidence of renal toxicity during induction [10] . In contrast, retrospective pharmacokinetic analyses of MTX serum concentrations after high-dose MTX in children with non-B cell ALL showed MTX system clearance decreased as a function of age (range 0.25-15 years), suggesting faster elimination in infants [11, 12] .
The inclusion of MTX in several ongoing and planned clinical trials for young children with brain tumors warrants further study of MTX disposition in these patients, especially due to methotrexate's tendency to accumulate within extra-axial spaces and tumor-associated fluid collections, thereby leading to delayed systemic MTX excretion and potential toxicity [17] [18] [19] [20] . Patients with brain tumors often develop various post-resection fluid collections, such as tumor-associated pseudocysts, subdural collections, or pseudomeningoceles, which may not communicate freely with normal cerebrospinal fluid (CSF) spaces. The association of these abnormal fluid collections with MTX pharmacokinetics has not been documented in infants and young children with brain tumors who have post-resection fluid collections. Therefore, we conducted a retrospective study of MTX pharmacokinetics in 75 infants and young children diagnosed with central nervous system (CNS) tumors and treated with intravenous MTX to determine how the presence of possibly sequestered intracranial fluid collections affects MTX disposition.
Patients and methods

Data set and study sample
The study was approved by the St. Jude Institutional Review Board. Records were reviewed for patients enrolled on institutional protocol St. Jude Young Children 2007 (SJYC07; NCT00602667) from December 1, 2007, until July 31, 2010 (n = 65), or treated on non-protocol treatment plans as per SJYC07 (January-November 2007; n = 10). Informed consent was obtained for all invasive procedures. Patient demographics, diagnosis, magnetic resonance (MR) imaging findings, MTX dosage, and results of plasma MTX analysis were reviewed.
Methotrexate administration and monitoring
Each HD-MTX dose was administered as a 24-h (h) infusion. The total MTX dosage (5,000 or 2,500 mg/m 2 , the latter an empiric dose reduction for patients <31 days old at treatment start due to the lack of available data regarding MTX disposition in children this young) was diluted in 5 % dextrose in water with 40 mEq/l sodium bicarbonate to a concentration of 10 mg/ml; 10 % of the total dosage (500 or 250 mg/m 2 , respectively) was administered as a loading dose over 1 h, followed by a 23-h infusion of the remaining 90 % (4,500 or 2,250 mg/m 2 , respectively). For clinical purposes, delayed plasma excretion was defined as an MTX concentration (MTX) >1.0 μM at 42 h. Prehydration with sodium bicarbonate at 200 ml/m 2 /h was initiated either at least 2 h before starting MTX and decreased to 125 ml/ m 2 /h after prehydration fluids were completed or started at 125 mL/m 2 /h for at least 6 h until the urine pH was 7-8. Standard leucovorin rescue was administered at 15 mg/m 2 / dose (intravenous or oral) starting at 42 h and given every 6 h for a total of 5 doses. For plasma (MTX) ≥1 μM at 42 h or clinical toxicity, the dosage, frequency, and duration of leucovorin rescue and/or rate of intravenous fluid hydration was increased.
Magnetic resonance (MR) imaging and analysis for patients
All MR images were acquired on one of two 1.5 T Avanto MR imagers (Siemens Medical Systems, Iselin, NJ) as 4-mm-thick contiguous axial oblique slices with whole-head coverage and a 256 matrix (voxel size 0.82 × 0.82 × 4 mm at 210 mm field-of-view). T2-weighted images were acquired with a spin-echo sequence (TR/TE = 5,570/119 ms, 1 acquisition) on an oblique plane defined by the most inferior extent of the genu and splenium of the corpus callosum. T2 images were first processed to extract the brain and surrounding fluid (Fig. 1 ). An empirically determined threshold was applied to the images to segment the fluid within them. Once a binary image of all T2-hyperintense voxels was created, the ventricles and any residual white matter hyperintensities were manually removed. A histogram analysis across all slices was performed to determine the total number of imaging voxels containing extra-axial fluid within normal subarachnoid space or abnormal collections, such as subdurals, epidurals, pseudomeningoceles, cysts, or other possible extra-axial fluid collections (e.g., arachnoidal cysts). This voxel count was then multiplied by the voxel volume to yield a total fluid volume in milliliters.
Brain MRIs from all patients obtained after tumor resection but before course 1 HD-MTX were reviewed for these abnormal fluid collections. Hydrocephalus was not used as a measurable collection because of its communication with 1 3 CSF spaces. In cases in which more than one fluid collection was present, volumes were summed.
Plasma methotrexate bioanalysis
Blood samples (1-2 ml) from patients' central lines were collected in K 2 EDTA tubes before MTX infusion and 6, 23, 42, and 66 h from start of the first infusion during course 1. Additional samples were collected if the patient's plasma (MTX) was not below 0.1 µM at 66 h. Samples were centrifuged at 7,000g for 10 min and MTX plasma concentrations determined by fluorescence polarization immunoassay (FPIA, TDx System; Abbott Laboratories, Abbott Park, IL). The lower limit of quantitation for plasma (MTX) was 0.03 μM.
Pharmacokinetic analysis
Nonlinear mixed-effects modeling (Monolix 3.1) was used to determine population and individual post hoc MTX pharmacokinetic parameters [21] . All data were obtained from course one of treatment. A two-compartment pharmacokinetic model with first-order elimination was fit to the data [22] [23] [24] [25] . Parameters estimated included systemic clearance (Cl), volume of distribution for each compartment (V 1 , V 2 ), and inter-compartmental clearance (Q). The distribution of the parameters was assumed log-normal. Data below the lower limit of quantification were censored and modeled using the likelihood approach described in Monolix. A proportional residual error model was used which assumed normal distribution of the residuals.
The association of both age and postoperative CNS fluid collection volume with the pharmacokinetic parameters was analyzed. These covariates were considered significant in a univariate analysis if their addition to the model reduced the objective function value at least 3.84 units (P < 0.05, based on Chi-square test for the difference in the −2 log-likelihood between 2 hierarchical models that differ by 1 degree of freedom), and the covariate term was significantly different than zero (t test, P < 0.05). The percent change in the inter-individual variability (IIV) was described by the percent change in the variance estimate (Ω 2 ) between the IIV of the base and covariate model. Two measures of delayed MTX excretion were considered. We determined whether the individual's estimated plasma (MTX) was >1.0 µM at 42 h (clinical indicator of whether additional leucovorin or intravenous fluid hydration is given) or >0.1 µM at 66 h. In addition, we estimated the time each individual's estimated plasma (MTX) remained above 0.1 µM. Analysis of variance was used to determine the effect of postoperative CNS fluid and age on threshold time.
Toxicities
Methotrexate toxicity was monitored and graded according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, version 3.0. All grades 3, 4, and 5 adverse events were documented. Dose limiting toxicities of MTX are generally bone marrow suppression, ulcerative stomatitis, severe diarrhea, and nephrotoxicity. The majority of identified toxicities were considered related to methotrexate if occurring within a week of administration and prior to the start of the next chemotherapy on day 8. The only exception was neurotoxicity, which can be a delayed complication.
Statistical analysis
Kruskal-Wallis (KW) tests were used to compare the differences in various pharmacokinetic and clinical parameters between two groups, e.g., patients with and without toxicities, fluid collections, etc. Associations between categorical variables were explored via Fisher's exact test. Correlations between continuous variables were explored via Pearson's correlation coefficient calculated on the natural log scale (PCC ln) to improve linearity and remove the influence of outliers. P values presented are not adjusted for multiplicity.
Results
Patient characteristics
Seventy-five infants and young children (45 male and 30 female) were treated with HD-MTX: 65 were enrolled on SJYC07 (for children <3 years old at diagnosis) and 10 were treated off protocol. Median age of patients at diagnosis was 1.6 years (range 8 days to 42 months). None of the patients were pretreated; all were newly diagnosed. Table 1 summarizes patient demographics, diagnosis, and details of MTX administration.
MR Imaging of CNS fluid collections
Abnormal intracranial fluid collections were identified in 58 patients following review of MRIs performed after surgery and prior to the first HD-MTX course. Specifically, there were 29 subdural, 1 epidural, and 13 other extra-axial fluid collections. In addition, four patients' MRIs demonstrated tumor cysts. Twenty-three patients had pseudomeningoceles. Twelve of the 58 patients had more than one type of fluid collection. The median (range) observed abnormal fluid collection volume was 375.8 ml/ m 2 (102.8-1,510.8 ml/m 2 ).
Pharmacokinetic analysis Table 2 summarizes the population MTX pharmacokinetic parameters for these infants and young children. Estimated population average (inter-individual variability) MTX clearance in our patients was 96.0 ml/min/m 2 (41.1 CV %). The results of the nonlinear mixed-effects analyses showed age and intracranial fluid volumes were significantly related to MTX pharmacokinetic parameters. MTX clearance and volume of distribution increased with age (P < 10 −4 and P < 0.002, respectively, Fig. 2a and b) . As a result, the −2 log-likelihood decreased 11.1 units (P < 10
−3
). The addition of age to the model explained 31 and 30 % of the inter-individual variability (IIV) in clearance and volume of distribution, respectively. In addition, higher intracranial fluid volume correlated with higher inter-compartmental clearance (Q; P < 10 
Toxicity
Of the 75 patients studied during course 1, only 11 MTXrelated grade 3 or 4 toxicities were observed. These included gastrointestinal toxicities (n = 7), dermatologic toxicities (n = 2), and metabolic/laboratory toxicities (n = 2). No grade 5 toxicities occurred. We investigated whether intracranial fluid collections, delayed MTX excretion, pre-or post-MTX hydration, or leucovorin rescue was related to the occurrence of these toxicities. In all cases, no significant relationships were observed; however, the power to detect such relationships was limited due to only 11/75 patients experiencing grade 3 or 4 MTX-related toxicities. At 5 % significance level based on Kruskal-Wallis test, this sample size has only 30 % power to detect an effect size of 0.5 standard deviation and 80 % power for an effect size of 1 standard deviation. Interestingly, our data suggested that patients who developed grade 3 or 4 toxicities tended to be younger compared to those who did not though the difference did not reach statistical significance (median 1.1 vs. 1.7 year; KW, P = 0.096).
Supportive care
We also studied how delayed excretion was affected by supportive care. We observed a significant increase in total post-MTX hydration in children with delayed excretion versus normal MTX excretion either defined as (MTX) >1.0 µM at 42 h (7.0 vs 7.7 l/m 2 , KW, P = 0.055) or as (MTX) >0.1 µM at 66 h (6.8 vs 8.1 l/m 2 ; KW, P = 0.005). With respect to intracranial fluid collections, we did not see a change in total pre-or post-MTX hydration, but we did observe a positive association between total leucovorin dose and intracranial fluid collection (PCC ln, r = 0.25, P = 0.03).
Discussion
Intravenous HD-MTX has been recognized as an active agent in treating pediatric brain tumors [6, 7] , thus its incorporation into treatment regimens for such tumors has led to concern that MTX may accumulate within sizeable, abnormal, sequestered intracranial fluid collections created by neurosurgical procedures. Sequestration of MTX in other third spaces such as pleural fluid and ascites has been documented to impact MTX clearance in lymphoid malignancies and solid tumors [17, 19, 26, 27] . Our study investigates the role of post-resection intracranial fluid collections on MTX disposition in infants and young children with brain tumors. The 66 h MTX concentrations were >0.1 µM more than three times as often in patients with intracranial fluid collections compared to those without fluid collections. Our data also suggest that patients with MTX concentrations >0.1 µM at 66 h had larger median intracranial fluid collections compared to those without an abnormal fluid collection. Neither the presence of abnormal fluid collection nor delayed MTX excretion was associated with the occurrence of grade 3 or 4 toxicity presumably due to close MTX monitoring that resulted in aggressive fluid management and protocol-guided leucovorin rescue for patients with delayed MTX excretion. Our ability to detect these associations, however, is limited by the small number of patients who experienced grade 3 or 4 toxicity in our cohort.
Clinically relevant CNS fluid collections are relatively rare in other patient populations, but common in patients with primary CNS malignancies, especially in the immediate postoperative setting [27] [28] [29] [30] [31] . These collections include postoperative subdural fluid collections (typically hygromas), pseudomeningoceles, or intracranial pseudocysts. Therefore, this population is ideal to examine the potential impact of intracranial fluid collections on MTX pharmacokinetics and toxicity and to study whether potential modifications to MTX administration (e.g., dosage) or monitoring (e.g., MTX concentrations, increase in fluid hydration, and changing leucovorin rescue) are required for these patients.
Several investigators have reported alterations in MTX pharmacokinetics due to the presence of fluid collections or third spaces [17, 18, [32] [33] [34] . Using a physiologically based pharmacokinetic model, Li and Gwilt assessed factors related to the extent to which methotrexate is sequestered into physiologic third spaces [19] . Results of their simulations showed that the volume of the third space, MTX protein binding in that space, and rate of transport into and out of the space were the key covariates related to methotrexate pharmacokinetic parameters (e.g., volume of distribution at steady-state and half-life). Thus, third spaces with more protein, higher methotrexate protein binding, or larger volumes will have an apparent increased volume of distribution at steady-state and longer terminal plasma half-lives. Protein concentration in the fluid collections observed in our patients was similar to that of CSF (e.g., 15-60 mg/dl), which is very low and should not alter MTX disposition [35] . As the fluid collection volume increased, we observed an increase in the inter-compartment clearance rate (Q), a term which is similar to permeability clearance (PA) used by Li and Gwilt to describe the transport rate into and out of third spaces [19] . The net effect of a higher Q on plasma MTX pharmacokinetics in our patients was to shift the start of the slower terminal elimination phase to a higher MTX concentration. This translated to a terminal phase that remained above 0.1 µM longer, resulting in delayed MTX excretion at 66 h.
At the outset of this clinical trial, little data were available upon which to base the selection of MTX monitoring guidelines for infants with brain tumors receiving HD-MTX. On the basis of unpublished guidelines from previous pediatric trials at our institution incorporating HD-MTX, we included an additional time point for methotrexate monitoring during the infusion at 6 h to provide an early indicator of whether a patient might have a low clearance and possibly high MTX systemic exposure, necessitating closer clinical monitoring. The remainder of the methotrexate monitoring was per our institutional guidelines with leucovorin rescue beginning at 42 h and delayed excretion based upon the methotrexate concentrations at 42 and 66 h. The definition of delayed excretion used in this study differs slightly from other current guidelines summarized in Table 3 [6, 7, [36] [37] [38] [39] [40] [41] .
In the Children's Oncology Group (COG) studies ACNS0333 and ACNS0334, suggested administration guidelines for HD-MTX with leucovorin rescue are provided based upon 24-, 48-, and 72-h MTX concentrations. Similar to the Head Start II (HS II) trial, these studies define delayed excretion as (MTX) ≥0.1 µM at 72 h [7, 36, 37, 40, 41] . Our patients with intracranial fluid collections had plasma MTX concentrations above the COG and HS II threshold of 0.1 µM at 72 h longer than those that did not (data not shown). In those patients with MTX plasma concentrations above the threshold of 0.1 µM, the median intracranial fluid volume was greater than those patients with MTX concentrations below the threshold (423 vs. 336 ml/m 2 ; P = 0.07). HD-MTX was well tolerated after the first course of therapy in our patients with grades 3 and 4 toxicities. We did observe an interesting trend for greater toxicities in younger patients similar to that observed by Thompson and colleagues in infants with ALL [10] , but more patients must be studied to fully understand this relationship. Younger children had a longer time above the threshold of 0.1 µM when controlling for the presence of an intracranial fluid collection. Thus, it is possible that age may affect the time for MTX serum concentrations to reach safe concentrations, indirectly reflecting the ontogeny of renal function [42, 43] . The tolerability of HD-MTX after one course among the majority of patients, however, should not obviate the need for careful monitoring and further study, especially as renal function may be further compromised by additional courses of therapy. The lack of significant clinical toxicities may be due to adjustments made to the posthydration fluid and leucovorin rescue per supportive care guidelines while being mindful of the presence of intracranial fluid collections.
Our study suggests that HD-MTX can be administered safely to children with transient or permanent postsurgical intracranial fluid collections, using intensive methotrexate monitoring, hydration, and leucovorin rescue. In patients younger than 1 year who have an intracranial fluid collection or those with compromised renal function, we recommend that plasma MTX concentrations be monitored until they are undetectable. 
